- Conditions
- Aspiration Pneumonias, Tube Feeding, Enteral Feeds
- Interventions
- (Arm 1): PEG, (Arm 2): PEG-J
- Procedure
- Lead sponsor
- Jerry Dang
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–32
of 32
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Parkinson's Disease
- Interventions
- Levodopa carbidopa intestinal gel (LCIG), Placebo gel, Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
- Drug · Device
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 5 more
- Conditions
- Dravet Syndrome
- Interventions
- LP352, Placebo
- Drug
- Lead sponsor
- Longboard Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 25
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 20 more
- Conditions
- Developmental and/or Epileptic Encephalopathies
- Interventions
- TAK-935, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Port Charlotte, Florida • Tampa, Florida + 8 more
- Conditions
- Monocarboxylate Transporter 8 Deficiency, Allan-Herndon-Dudley Syndrome
- Interventions
- Tiratricol
- Drug
- Lead sponsor
- Rare Thyroid Therapeutics International AB
- Industry
- Eligibility
- Not listed
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Madera, California • San Diego, California + 13 more
- Conditions
- Advanced Parkinson's Disease
- Interventions
- Levodopa carbidopa intestinal gel (LCIG), Placebo Gel, Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
- Drug · Device
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Oceanside, California + 8 more
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
- Interventions
- sunitinib malate, pharmacological study, 3-dimensional conformal radiation therapy, cetuximab
- Drug · Other · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 12
- States / cities
- Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 9 more
- Conditions
- Feeding Tube
- Interventions
- PEG-J placement
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland